Published in Cell Immunol on February 01, 1983
Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med (1984) 2.33
Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci U S A (1989) 2.06
Interferon gamma induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci U S A (1987) 1.03
Gamma interferon prevents diabetes in the BB rat. Clin Diagn Lab Immunol (1997) 0.78
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell (1996) 9.93
MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature (1997) 6.53
Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity (1998) 6.07
A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem (1995) 5.34
Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature (1982) 3.74
Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity (2000) 3.61
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med (1992) 3.37
Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. Proc Natl Acad Sci U S A (1982) 3.11
Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem (1990) 2.99
Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A (1980) 2.88
Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem (1995) 2.78
The death domain: a module shared by proteins with diverse cellular functions. Trends Biochem Sci (1995) 2.70
TNF stimulates expression of mouse MHC class I genes by inducing an NF kappa B-like enhancer binding activity which displaces constitutive factors. EMBO J (1989) 2.65
Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol (1999) 2.39
A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem (1989) 2.35
Soluble cytokine receptors are present in normal human urine. J Exp Med (1989) 2.24
Tumor necrosis factor induction by Sendai virus. J Immunol (1986) 2.14
Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem (1990) 2.12
Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor. Infect Immun (1988) 2.04
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol (1994) 1.83
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A (1998) 1.81
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
CASH, a novel caspase homologue with death effector domains. J Biol Chem (1997) 1.72
Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. EMBO J (1983) 1.71
Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res (1991) 1.68
Caspase-8 deficiency facilitates cellular transformation in vitro. Cell Death Differ (2008) 1.64
Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol (1984) 1.64
CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem (1998) 1.64
Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet (1981) 1.59
Calcium and the exportable protein in rat parotid gland. Parallel subcellular distribution and concomitant secretion. Eur J Biochem (1971) 1.52
Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc Natl Acad Sci U S A (1999) 1.42
Marriage: a 19th century French method for the prevention of syphilis: reflections on the control of AIDS. Int J Dermatol (1993) 1.41
[Thalidomide and thrombosis]. Ann Dermatol Venereol (2000) 1.40
Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J (1992) 1.39
Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res (1992) 1.33
TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein. J Immunol (1994) 1.32
Reversion of the antichlamydial effect of tumor necrosis factor by tryptophan and antibodies to beta interferon. Infect Immun (1989) 1.28
Monitoring of interferon therapy by assay of (2'--5') oligo-isoadenylate synthetase in human peripheral white blood cells. J Interferon Res (1981) 1.27
Increase of vulnerability to lymphotoxin in cells infected by vesicular stomatitis virus and its further augmentation by interferon. Cell Immunol (1985) 1.26
Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest (1998) 1.24
Stimulation of guanylate cyclase of fibroblasts by free fatty acids. J Biol Chem (1976) 1.24
A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other. J Exp Med (1996) 1.23
Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. J Cereb Blood Flow Metab (1996) 1.23
Studies on T cell subsets and functions in leprosy. Clin Exp Immunol (1981) 1.22
Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodies. J Immunol (1981) 1.18
Non-parallel transport of membrane proteins and content proteins during assembly of the secretory granule in rat parotid gland. Biochim Biophys Acta (1975) 1.17
A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J (1999) 1.17
Biogenesis of chloroplast membranes. IX. Development of photophosphorylation and proton pump activities in greening Chlamydomonas reinhardi y-I as measured with an open-cell preparation. Biochim Biophys Acta (1972) 1.15
Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol (1987) 1.12
The interferon-induced enzyme oligo-isoadenylate synthetase: rapid determination of its in vitro products. Anal Biochem (1981) 1.10
Self-association of chicken gizzard filamin and heavy merofilamin. Biochemistry (1980) 1.09
Filamin-actin interaction. Dissociation of binding from gelation by Ca2+-activated proteolysis. J Biol Chem (1978) 1.09
Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria. Cytokine (1993) 1.09
Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor. J Biol Chem (1994) 1.08
Metastatic cutaneous Crohn's disease in a child. J Pediatr Gastroenterol Nutr (1998) 1.08
Tumor necrosis factor in middle ear effusions. Arch Otolaryngol Head Neck Surg (1988) 1.08
Cachectin/tumour-necrosis-factor production by cancer patients. Lancet (1985) 1.08
Binding of human TNF-alpha to high-affinity cell surface receptors: effect of IFN. Immunol Lett (1986) 1.06
Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.06
Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol (1992) 1.05
Apoptosis. Placing death under control. Nature (1997) 1.05
Involvement of interferon in virus-induced lymphopenia. Cell Immunol (1983) 1.04
Cytotoxins (tumour necrosis factor, lymphotoxin and others): molecular and functional characteristics and interactions with interferons. Interferon (1986) 1.03
Dual role of the p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity. J Exp Med (1994) 1.03
Soluble tumor necrosis factor receptors and interleukin-6 levels in patients with severe preeclampsia. Obstet Gynecol (1996) 1.03
Development of the acetabulum and hip: computed tomography analysis of the axial plane. J Pediatr Orthop (1993) 1.02
Interferon-induced enzymes: microassays and their applications: purification and assay of (2'-5')-oligoadenylate synthetase and assay of 2'-phosphodiesterase. Methods Enzymol (1981) 1.02
Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. Cytokine (1993) 1.01
Intramuscular human interferon-beta injections in treatment of condylomata acuminata. Lancet (1984) 1.01
Comparison of (2'-5') oligo-adenylate synthetase and interferon blood-levels in mice early after viral infection. J Interferon Res (1982) 1.01
Extracellular matrix induces tumour necrosis factor-alpha secretion by an interaction between resting rat CD4+ T cells and macrophages. Immunology (1993) 0.99
Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol (1992) 0.98
Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein. Proc Natl Acad Sci U S A (1985) 0.96
[Plasma exchange in the treatment of lepromatous leprosy]. Acta Leprol (1980) 0.96
Cyclic AMP-dependent phosphorylation of filamin in mammalian smooth muscle. J Biol Chem (1978) 0.96
Cyclic AMP-dependent phosphorylation of the actin-binding protein filamin. Adv Cyclic Nucleotide Res (1978) 0.96
Purification of soluble cytokine receptors from normal human urine by ligand-affinity and immunoaffinity chromatography. J Chromatogr (1990) 0.96
A protein related to a proteasomal subunit binds to the intracellular domain of the p55 TNF receptor upstream to its 'death domain'. FEBS Lett (1995) 0.95
Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol (1993) 0.95
Imbalances in T cell subpopulations in lepromatous leprosy. Int J Lepr Other Mycobact Dis (1982) 0.94
Soluble TNF receptor production by activated T lymphocytes: differential effects of acute and chronic exposure to TNF. Immunology (1995) 0.93
Tissue distribution of streptozotocin (NSC-85998). Cancer Chemother Rep (1974) 0.93
[The history of nosology in dermatology]. Ann Dermatol Venereol (1989) 0.92
Activation of adenylate cyclase in cultured fibroblasts by trypsin. J Biol Chem (1978) 0.91
TRAF2 plays a dual role in NF-kappaB-dependent gene activation by mediating the TNF-induced activation of p38 MAPK and IkappaB kinase pathways. FEBS Lett (1998) 0.91
Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells. J Immunol (1988) 0.90
Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood (1993) 0.89
Inhibition of growth of Chlamydia trachomatis by tumor necrosis factor is accompanied by increased prostaglandin synthesis. Infect Immun (1990) 0.87
Specificity study of PPD-reactive human T cell line and clones. Immunol Lett (1985) 0.87
Soluble tumor necrosis factor receptors and soluble interleukin-6 receptor in fetal and maternal sera, coelomic and amniotic fluids in normal and pre-eclamptic pregnancies. J Reprod Immunol (1995) 0.87
The gene for the type II (p75) tumor necrosis factor receptor (TNF-RII) is localized on band 1p36.2-p36.3. Hum Genet (1991) 0.86
Variation of (2'-5') oligo A synthetase level in lymphocytes and granulocytes of patients with viral infections and leukemia. J Interferon Res (1982) 0.86
An interferon-induced cellular enzyme is incorporated into virions. Nature (1980) 0.86
Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor. Gene (1993) 0.86
In vitro proliferative response to M. leprae and PPD of isolated T cell subsets from leprosy patients. Clin Exp Immunol (1983) 0.86
Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo. Pharm Res (2000) 0.85
Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability. Immunobiology (1988) 0.85